Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rare blood disorder

- PMLiVE

Amgen’s interchangeable Soliris biosimilar Bkemv approved by FDA for rare blood disorders

Bkemv has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with C3G every year

- PMLiVE

Sobi’s Aspaveli receives expanded EC approval for rare blood disorder PNH

The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria

- PMLiVE

Novartis and PeptiDream expand peptide discovery collaboration in deal worth over $2.8bn

The agreement builds on the companies’ peptide-drug conjugate collaboration announced in 2019

- PMLiVE

Novartis’ Lutathera receives FDA approval to treat neuroendocrine tumours in paediatric patients

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

Novartis’ targeted combination therapy recommended by NICE to treat childhood brain tumours

Gliomas are the most common type of brain cancer in paediatric patients

- PMLiVE

AstraZeneca’s Voydeya granted EC approval to treat rare blood disease PNH

The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors

- PMLiVE

Novartis presents positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

- PMLiVE

Novartis’ blood cancer therapy Kymriah recommended by NICE for routine NHS use

In England, ALL is responsible for around 300 new diagnoses every year in people aged 25 years and under

- PMLiVE

Novartis gains rights to Arvinas’ prostate cancer therapy in deal worth over $1bn

The transaction also includes the sale of Arvinas’ preclinical AR-V7 programme

- PMLiVE

Novartis shares positive real-world data for Leqvio in atherosclerotic CVD

LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links